Meteospasmyl

-A A +A
Pharmaceutical form: 
Soft capsules
Composition: 

Alverini citras 60 mg and simeticonum 300 mg in 1 capsule

Pharmacological properties: 

Meteospasmyl is a combined preparation containing alverine, a spasmolytic agent with a direct effect on the smooth muscle of the digestive tract. Alverine is more effective than papaverine and exerts fewer undesirable effects. The second component of the preparation is simethicone, which by a physical mechanism decreases the formation of gas and facilitates its removal from the digestive tract.

Pharmacotherapeutic group: 

Spasmolytic agent, deflatulent (ATC code: A03AX58)

Therapeutic indications: 

Symptomatic treatment of functional intestinal disorders accompanied by abdominal pains or even painful spasms, compulsive diarrhoea, meteorism and flatulence. Particularly, the irritable colon is concerned. The preparation is intended only for adults.

Contraindications: 

Hypersensitivity to any component of the preparation, ileus conditions, pregnancy and lactation, children and adolescents under 18 years of age.

Undesirable effects: 

Meteospasmyl is usually very well tolerated, undesirable effects are sporadic and transitory. In the course of treatment, headache, dry mouth, nausea, weakness, vertigo, and decreased blood pressure may occur. Very rarely allergic skin rash may develop.

Interactions: 

No interactions of Meteospasmyl with other drugs have been reported.

Special warnings and precautions for use: 

Caution is required when signs preceding ileus (nausea, vomiting, abdominal pains, blocking of wind and stool) occur.

Posology and method of administration: 

Usually 1 capsule is administered 2 to 3 times a day before meals, for a period of 3 to 4 weeks. Capsules are swallowed whole, unchewed, and are washed down with a sufficient amount of liquid.

Contents of container: 

20 capsules

Package available in the Czech Republic: 

Not marketed.

Date of revision of the text: 
29 October 2009

For more detailed product information, see the Summary of Product Characteristics.

The medicinal product is sold over the counter and not marketed.
Marketing authorisation holder:
LABORATOIRES MAYOLY SPINDLER, 6, avenue de l’Europe – B.P. 51, 78 401 Chatou Cedex, France